Antitumor effect of conditioned media derived from murine MSCs and 5-aminolevulinic acid (5-ALA) mediated photodynamic therapy in breast cancer in vitro

Photodiagnosis and Photodynamic Therapy

Volumn 12, Issue 2, 2015, Pages 238-243

  Mohammadpour, Hemn ^a   Majidzadeh A, Keivan ^b,c  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b AVICENNA RESEARCH INSTITUTE   (Iran)

^c AJA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Breast cancer; Mesenchymal stem cells; Photodynamic therapy; TRAIL

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; AMINOLEVULINIC ACID; BETA1 INTEGRIN; CD44V ANTIGEN; DICKKOPF 1 PROTEIN; DICKKOPF 3 PROTEIN; GLYCOPROTEIN; MITOCHONDRIAL ENZYME; OXIDOREDUCTASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; CONDITIONED MEDIUM; DKK1 PROTEIN, MOUSE; DKK3 PROTEIN, MOUSE; PHOTOSENSITIZING AGENT; SIGNAL PEPTIDE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CELL PROLIFERATION; DIODE LASER; ENZYME ACTIVITY; FLOW CYTOMETRY; IN VITRO STUDY; MESENCHYMAL STEM CELL; MOUSE; MTT ASSAY; MURINAE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RED LIGHT; ANIMAL; BIOSYNTHESIS; BREAST NEOPLASMS; CONDITIONED MEDIUM; DRUG EFFECTS; FEMALE; MESENCHYMAL STROMA CELL; PHOTOCHEMOTHERAPY; PHYSIOLOGY; PROCEDURES; TUMOR CELL LINE;

MURINAE;

AMINOLEVULINIC ACID; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; FEMALE; FLOW CYTOMETRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LASERS, SEMICONDUCTOR; MESENCHYMAL STROMAL CELLS; MICE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84930474065     PISSN: 15721000     EISSN: 18731597     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2015.02.004     Document Type: Article

References (30)

1. García-Gómez I., Elvira G., Zapata A.G., Lamana M.L., Ramírez M., García Castro J., et al. Mesenchymal stem cells: biological properties and clinical applications. Exp Opin Biol Ther 2010, 10:1453-1468.
2. Caplan A.I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007, 213:341-347.
3. Sun B., Roh K.-H., Park J.-R., Lee S.-R., Park S.-B., Jung J.-W., et al. Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. Cytotherapy 2009, 11:289-298.
4. Shah K. Mesenchymal stem cells engineered for cancer therapy. Adv Drug Deliv Rev 2012, 64:739-748.
5. Kim S.M., Oh J.H., Park S.A., Ryu C.H., Lim J.Y., Kim D.S., et al. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem Cells 2010, 28:2217-2228.
6. Lee R.H., Yoon N., Reneau J.C., Prockop D.J. Preactivation of human MSCs with TNF-α enhances tumor-suppressive activity. Cell Stem Cell 2012, 11:825-835.
7. Qiao L., Xu Z.-l., Zhao T.-j., Ye L.-h., Zhang X.-d. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett 2008, 269:67-77.
8. Kawasaki K., Watanabe M., Sakaguchi M., Ogasawara Y., Ochiai K., Nasu Y., et al. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer. Cancer Gene Ther 2008, 16:65-72.
9. Corsten M.F., Shah K. Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare. Lancet Oncol 2008, 9:376-384.
10. Triesscheijn M., Baas P., Schellens J.H., Stewart F.A. Photodynamic therapy in oncology. Oncologist 2006, 11:1034-1044.
11. Diez B., Ernst G., Teijo M.J., Batlle A., Hajos S., Fukuda H. Combined chemotherapy and ALA-based photodynamic therapy in leukemic murine cells. Leuk Res 2012, 36:1179-1184.
12. Granville D.J., Jiang H., McManus B.M., Hunt D.W. Fas ligand and TRAIL augment the effect of photodynamic therapy on the induction of apoptosis in JURKAT cells. Int Immunopharmacol 2001, 1:1831-1840.
13. Tsai T., Hong R.L., Tsai J.C., Lou P.J., Ling I., Chen C.T. Effect of 5-aminolevulinic acid-mediated photodynamic therapy on MCF-7 and MCF-7/ADR cells. Lasers Surg Med 2004, 34:62-72.
14. Nakamura K., Ito Y., Kawano Y., Kurozumi K., Kobune M., Tsuda H., et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004, 11:1155-1164.
15. Watanabe M., Kashiwakura Y., Huang P., Ochiai K., Futami J., Li S.-A., et al. Immunological aspects of REIC/Dkk-3 in monocyte differentiation and tumor regression. Int J Oncol 2009, 34:657-663.
16. Gregory C.A., Singh H., Perry A.S., Prockop D.J. The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J Biol Chem 2003, 278:28067-28078.
17. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006, 127:469-480.
18. Lu Y-r, Yuan Y., Wang X-j, Wei L-l, Chen Y-n, Cong C., et al. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther 2008, 7:245-251.
19. Khakoo A.Y., Pati S., Anderson S.A., Reid W., Elshal M.F., Rovira I.I., et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006, 203:1235-1247.
20. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
21. Waterman R.S., Henkle S.L., Betancourt A.M. Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. PLos ONE 2012, 7:e45590.
22. Du J., Zhou L., Chen X., Yan S., Ke M., Lu X., et al. IFN-γ-primed human bone marrow mesenchymal stem cells induce tumor cell apoptosis in vitro via tumor necrosis factor-related apoptosis-inducing ligand. Int J Biochem Cell Biol 2012, 44:1305-1314.
23. Hellwig C.T., Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther 2012, 11:3-13.
24. Kimberley F.C., Screaton G.R. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004, 14:359-372.
25. Szliszka E., Kawczyk-Krupka A., Czuba Z.P., Sieron A., Krol W. Effect of ALA-mediated photodynamic therapy in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on bladder cancer cells. Central Eur J Urol 2011, 64:175.
26. Sazgarnia A., Montazerabadi A.R., Bahreyni-Toosi M.H., Ahmadi A., Aledavood A. In vitro survival of MCF-7 breast cancer cells following combined treatment with ionizing radiation and mitoxantrone-mediated photodynamic therapy. Photodiagn Photodyn Ther 2013, 10:72-78.
27. Wazer D., Rogers G., Graham R. A phase 1 trial of a novel photodynamic therapy for chest wall recurrent breast cancer following prior radiation therapy. Int J Radiat Oncol Biol Phys 2014, 90:S243.
28. Yamashita K., Hagiya Y., Nakajima M., Ishizuka M., Tanaka T., Ogura S.-i. The effects of the heme precursor 5-aminolevulinic acid (ALA) on REV-ERBα activation. FEBS Open Biol 2014, 4:347-352.
29. Acedo P., Stockert J., Cañete M., Villanueva A. Two combined photosensitizers: a goal for more effective photodynamic therapy of cancer. Cell Death Dis 2014, 5:e1122.
30. Granville D., Hunt D. Porphyrin-mediated photosensitization-taking the apoptosis fast lane. Curr Opin Drug Discov Dev 2000, 3:232-243.